Pyrotinib (Synonyms: SHR-1258)

Name: Pyrotinib
Brand: MedChemExpress
SKU: HY-104065
Rating: 5.0 (18 reviews)

Cat. No.: HY-104065 Pureza: 99.89%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1269662-73-8

Tamaño	Stock	Cantidad
Muestra gratis (0.1 - 0.2 mg)	Solicite ahora
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
250 mg	En stock	Estimated Time of Arrival: December 31
500 mg	Obtener un presupuesto
1 g	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 18 publication(s) in Google Scholar

Other Forms of Pyrotinib:

(Rac)-Pyrotinib In-stock
Pyrotinib dimaleate In-stock
Pyrotinib (Standard) Obtener un presupuesto

18 Publications Citing Use of MCE Pyrotinib

Cell Proliferation/Viability Assay

IHC

Cell Imaging/Staining

Apoptosis Analysis

: Pyrotinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]; Primary gastric cancer (GC-1 and GC-2) cells treated with Pyrotinib, Dacomitinib, Afatinib, or DMSO (control) at 1 µM concentration over 3 days, growth curves represent three independent experiments.

: Pyrotinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]; Western blotting analysis showed the cleaved caspase-9 level in GC cells treated with different dose of Pyrotinib (0.5, 1, 2 μM).

: Pyrotinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]; Representative immunohistochemical staining of Ki-67 and phosphorylated EGFR (p-EGFR) in xenograft tumor tissues excised from indicated mice treated with Pyrotinib (10 mg/kg, p.o.).

: Pyrotinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]; Representative TUNEL immunostaining (green) of apoptosis in xenograft tumor tissues excised from indicated mice treated with Pyrotinib (10 mg/kg, p.o.).

: Pyrotinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]; GC cells were harvested and stained with Annexin V-FITC and PI for apoptotic analysis with increasing concentrations of Pyrotinib (0.5, 1, 1.5, 2 μM) treatment for 48 h.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas EGFR:

Ver todas las isoformas

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

Actividad biológica
Protocolo
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC₅₀s of 13 and 38 nM, respectively^[1].

IC₅₀ & Target^[1]

EGFR

13 nM (IC₅₀)

HER2

38 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
BT-474	IC₅₀	3.97 nM Compound: Pyrotinib	Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
BaF3	IC₅₀	15 nM Compound: Pyrotinib	Antiproliferative activity against mouse BaF3 cells harbouring HER2 A775_G77insYVMA mutant assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against mouse BaF3 cells harbouring HER2 A775_G77insYVMA mutant assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
BaF3	IC₅₀	24.67 nM Compound: Pyrotinib	Antiproliferative activity against mouse BaF3 cells harboring HER2 YVMA mutant by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring HER2 YVMA mutant by CellTiter-Glo assay	[PMID: 38518121]
COLO-678	IC₅₀	1836.96 nM Compound: Pyrotinib	Antiproliferative activity against human COLO-678 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human COLO-678 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
ES-2	IC₅₀	778.34 nM Compound: Pyrotinib	Antiproliferative activity against human ES2 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human ES2 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
MDA-MB-468	IC₅₀	659.49 nM Compound: Pyrotinib	Antiproliferative activity against human MDA-MB-468 cells overexpressing wild type EGFR assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human MDA-MB-468 cells overexpressing wild type EGFR assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
MFE-280	IC₅₀	1559.06 nM Compound: Pyrotinib	Antiproliferative activity against human MFE-280 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human MFE-280 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
NCI-H441	IC₅₀	1886.34 nM Compound: Pyrotinib	Antiproliferative activity against human NCI-H441 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human NCI-H441 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
NCI-N87	IC₅₀	0.85 nM Compound: Pyrotinib	Antiproliferative activity against human NCI-N87 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human NCI-N87 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
NUGC-4	IC₅₀	60.8 nM Compound: Pyrotinib	Antiproliferative activity against human NUGC-4 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human NUGC-4 cells assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]
SK-BR-3	IC₅₀	14 nM Compound: Pyrotinib	Antiproliferative activity against human SK-BR-3 cells overexpressing wild type HER2 assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay Antiproliferative activity against human SK-BR-3 cells overexpressing wild type HER2 assessed as cell growth inhibition incubated for 72 hrs by Celltiter-Glo assay	[PMID: 35319895]

In Vitro

Pyrotinib has high potency in HER2-dependent cell lines (BT474, SK-OV-3), while showing much weaker inhibition in the HER2 negative cell line (MDA-MB-231). It inhibits BT474 and SK-OV-3Pyrotinib cells with IC₅₀s of 5.1 and 43 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pyrotinib has acceptable bioavailability of 20.6%, 43.5% and 13.5% in nude mice, rats and dogs, respectively. The TGI % (tumor growth inhibition) of Pyrotinib on day 21 is 109%, 157%, 159% at the doses of 5 mg/kg, 10 mg/kg, 20 mg/kg respectively. Pyrotinib in SK-OV-3 ovarian xenograft model shows TGI% on day 21 of 2%, 12%, 83% at the doses of 2.5 mg/kg, 5 mg/kg, 10 mg/kg respectively), which further confirms its robust in vivo antitumor efficacy at 10 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

Peso molecular

583.08

Fòrmula

C₃₂H₃₁ClN₆O₃

No. CAS

1269662-73-8

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvente y solubilidad

In Vitro:

1 M Maleic Acid : 100 mg/mL (171.50 mM; Need ultrasonic)

0.1 M Maleic Acid : 16.67 mg/mL (28.59 mM; Need ultrasonic)

DMSO : 10 mg/mL (17.15 mM; ultrasonic and adjust pH to 6 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7150 mL	8.5752 mL	17.1503 mL
5 mM	0.3430 mL	1.7150 mL	3.4301 mL
10 mM	0.1715 mL	0.8575 mL	1.7150 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Pureza y Documentación

Purity: 99.89%

Select Batch:

Ficha de datos (275 KB) SDS (394 KB)

COA (249 KB) HNMR (287 KB) LCMS (94 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X. [Content Brief]

Ensayo celular ^[1]	Cancer cells (A431, SK-BR-3 and NCI-N87) are treated with a series of concentrations of Pyrotinib for 72 hours. Cell proliferation is determined by a sulforhodamine B (SRB) method. The IC₅₀ values are calculated by the data of inhibition rates of serial concentrations of test compounds^[1]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Administraciòn de animales ^[1]	Rats: Test compounds (include Pyrotinib) are administrated in both intravenous (i.v.) and intragastric (i.g.) for mice to obtain their bioavailability. Plasma samples of nude mice is collected at pre-dose and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h after the IV administration^[1]. Mice: In vivo efficacy studies are performed on BALB/Ca-nude mice (6 to 7 weeks, female) from SLAC. Nude mice are hypodermic inoculated BT-474 human breast cancer cell or SK-OV-3 ovarian cancer cell. After tumor grows to 150-250 mm³, mice are randomly divided into groups and dosed with Pyrotinib (2.5, 5, 10, 20 mg/kg) once daily. The volume of tumors and the weight of the mice are measured and recorded for 2-3 times per week^[1]. MCE no ha confirmado la precisión de estos métodos independientemente. Son solo para referencia.
Referencias	[1]. Li X, et al. Discovery and development of Pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / 0.1 M Maleic Acid / 1 M Maleic Acid	1 mM	1.7150 mL	8.5752 mL	17.1503 mL	42.8758 mL
	5 mM	0.3430 mL	1.7150 mL	3.4301 mL	8.5752 mL
	10 mM	0.1715 mL	0.8575 mL	1.7150 mL	4.2876 mL
	15 mM	0.1143 mL	0.5717 mL	1.1434 mL	2.8584 mL
0.1 M Maleic Acid / 1 M Maleic Acid	20 mM	0.0858 mL	0.4288 mL	0.8575 mL	2.1438 mL
0.1 M Maleic Acid / 1 M Maleic Acid	25 mM	0.0686 mL	0.3430 mL	0.6860 mL	1.7150 mL
1 M Maleic Acid	30 mM	0.0572 mL	0.2858 mL	0.5717 mL	1.4292 mL
	40 mM	0.0429 mL	0.2144 mL	0.4288 mL	1.0719 mL
	50 mM	0.0343 mL	0.1715 mL	0.3430 mL	0.8575 mL
	60 mM	0.0286 mL	0.1429 mL	0.2858 mL	0.7146 mL
	80 mM	0.0214 mL	0.1072 mL	0.2144 mL	0.5359 mL
	100 mM	0.0172 mL	0.0858 mL	0.1715 mL	0.4288 mL

Pyrotinib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pyrotinib1269662-73-8SHR-1258SHR1258SHR 1258EGFREpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Pyrotinib (Synonyms: SHR-1258)

Revisión del cliente

Other Forms of Pyrotinib:

Pyrotinib Related Antibodies

18 Publications Citing Use of MCE Pyrotinib

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas EGFR:

Actividad biológica

Protocolo

Pureza y Documentación

Referencias

Revisión del cliente

Pyrotinib Related Antibodies

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Pyrotinib Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report